MAM
PTGX icon

Marquette Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Marquette Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.43K Hold
28
– – ﹤0.01% 487
2026
Q1 		$2.95K Hold
28
– – ﹤0.01% 445
2025
Q4 		$2.45K Hold
28
– – ﹤0.01% 449
2025
Q3 		$1.86K Buy
+28
New +$1.59K ﹤0.01% 562

Other funds holding PTGX

MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return
CA
Cache Advisors San Francisco, California $1.18B AUM 44.04% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
BC
Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Marquette Asset Management's PTGX Position: Q2 2026 in Review

Marquette Asset Management held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 28 shares worth $3.43K. The position accounts for ﹤0.01% of the portfolio, ranked #487.

Marquette Asset Management first reported a position in PTGX in Q3 2025 and has held it in 4 quarters since. 25 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Marquette Asset Management held 28 shares of Protagonist Therapeutics worth $3.43K as of Q2 2026.
  • Marquette Asset Management left its Protagonist Therapeutics share count unchanged in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Marquette Asset Management's portfolio in Q2 2026, its #487 holding.
  • Marquette Asset Management first reported a position in Protagonist Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 25 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Marquette Asset Management's 13F filing for Q2 2026, filed 9 Jul 2026.